Peripheral edema, particularly of the lower limbs, is one of the most common adverse effects of dihydropyridine calcium channel blockers and may result in the need for dose reduction or drug ...
The Global Edema Clinical Trials Market is valued at approximately USD 877.31 million in 2023 and is anticipated to grow with a healthy growth rate of more than 5.7% over the forecast period 2024-2032 ...
Calcium channel blocker (CCB)-related edema is quite common in clinical practice and can effectively deter a clinician from continued prescription of these drugs. Its etiology relates to a ...